Protein kinase C inhibition and diabetic retinopathy: A shot in the dark at translational research

British Journal of Ophthalmology

Volumn 88, Issue 1, 2004, Pages 145-151

  Donnelly, R ^a,b   Idris, I ^b   Forrester, J V ^c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM); PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; VASCULOTROPIN;

CLINICAL TRIAL; DIABETIC RETINOPATHY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; EXPERIMENTAL MODEL; FEASIBILITY STUDY; HUMAN; HYPERGLYCEMIA; IC 50; LASER COAGULATION; LEUKOCYTE ADHERENCE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERMEABILITY; PRIORITY JOURNAL; RETINA BLOOD FLOW; RETINA MACULA EDEMA; REVIEW; SIDE EFFECT;

DIABETIC RETINOPATHY; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; INDOLES; MALEIMIDES; PROTEIN KINASE C; RANDOMIZED CONTROLLED TRIALS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0346494560     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.88.1.145     Document Type: Review

References (61)

1. Zhang LY, Krzentowski G, Albert A, et al. Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control. Diabetes Care 2001;24:1275-9.
2. Porta M, Bandello F. Diabetic retinopathy: an update. Diabetologia 2002;45:1617-34.
3. Idris I, Gray S, Donnelly R. Protein kinase C activation: isozyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologia 2001;44:659-73.
4. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1988;334:661-5.
5. Huang Q, Yuan Y. Interaction of PKC and NOS in signal transduction of microvascular hyperpermeability. Am J Physiol 1997;273:H2442-51.
6. Park J-Y, Takahara N, Gabriele A, et al. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes 2000;49:1239-48.
7. Williams B, Gallacher B, Patel H, et al. Glucose induced protein kinase C activation regulates vascular permeability factor (VEGF) mRNA expression and peptide production by human vascular smooth muscle cells in vitro. Diabetes 1997;46:1497-503.
8. Pomero F, Allione A, Beltramo E, et al. Effects of protein kinase C inhibition and activation on proliferation and apoptosis of bovine retinal pericytes. Diabetologia 2003;46:416-19.
9. Aiello LP, Northrup J, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995;113:1538-44.
10. Liao D-F, Monia B, Dean N, et al. Protein kinase C-ζ mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells. J Biol Chem 1997;272:6146-50.
11. Housey GM, O'Brien CA, Johnson MD, et al. Isolation of cDNA clones encoding protein kinase C: evidence for a protein kinase C-related gene family. Proc Natl Acad Sci USA 1987;84:1065-9.
12. Hug H, Sarre TF. Protein kinase C isoenzymes: divergence in signal transduction? Biochem J 1993;291:329-43.
13. Craven PA, Davidson PM, DeRubertis FR. Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes 1990;39:667-74.
14. Shiba T, Inoguchi T, Sportsman JR, et al. Correlation of diacylglycerol and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 1993;265:E783-93.
15. Inoguchi T, Battan R, Handler E, et al. Preferential elevation of protein kinase C isoform-beta II and diacylglycerol levels in the aorta and heart af diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992;89:11059-63.
16. Knott RM, Keenan FE, Muckersie E, et al. Glucose-dependent decreased DNA synthesis in bovine retinal endothelial cells is mediated by protein kinase C-iota. Bochem Soc Trans 1998;26:S260.
17. Ceolotto G, Gallo A, Miola M, et al. Protein kinase C activity is acutely regulated by plasma glucose concentration in human monocytes in vivo. Diabetes 1999;48:1316-22.
18. Ozaki H, Hayashi H, Vinores SA, et al. Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res 1997;64:505-17.
19. Aiello LP, Avery A, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluids of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
20. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457-61.
21. Jakeman LB, Winer J, Bennett GL, et al. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 1992;89:244-53.
22. Xia P, Aiello L, Ishii H, et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms and endothelial cell growth. J Clin Invest 1996;98:2018-26.
23. Suzama K, Takahara N, Suzuma I, et al. Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation and retinal neovascularization. Proc Natl Acad Sci USA 2002;99:721-6.
24. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997;46:1473-80.
25. Park CW, Kim JH, Lee JW, et al. High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-κB-dependent. Diabetologia 2000;43:1544-53.
26. Studer RK, Craven PA, DeRubertis F. Role of protein kinase C in the mediation of increased fibronectin accumulation by mesangial cells grown in high-glucose medium. Diabetes 1993;42:118-26.
27. Koya D, Jirousek MR, Lin Y-W, et al. Characterisation of protein kinase C β isoform activation on the gene expression of transforming growth factor-β extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997;100:115-26.
28. Miyamoto K, Hiroshiba N, Tsujikawa A, et al. In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci 1998;39:2190-4.
29. Barouch FC, Miyamoto K, Allport JR, et al. Integrin-mediated neutophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci 2000;41:1153-8.
30. Schroder S, Palinski W, Schmidt-Schonbein GW. Activated monocytes and granulocytes, capillary non-perfusion and neovascularization in diabetes retinopathy. Am J Pathol 1991;139:81-100.
31. Miyamoto K, Khosrof S, Bursell SE, et al. Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). Am J Pathol 2000;56:1733-9.
32. Ishibashi T, Tanaka K, Taniguchi Y. Platelet aggregation and coagulation in the pathogenesis of diabetic retinopathy in rats. Diabetes 1981;30:601-6.
33. Olson JA, Whitelaw CM, McHardy KC, et al. Soluble leucocyte adhesion molercules in diabetic retinopathy stimulate retinal capillary endothelial cell migration. Diabetologia 1997;40:1166-71.
34. Xia P, Kramer RM, King GL. Identification of the mechanism for the inhibition of Na-K-adenosine triphosphatase by hyperglycaemia involving activation of protein kinase C and cytosolic phospholipase A2. J Clin Invest 1995;96:733-40.
35. Kowluru RA, Jirousek MR, Stramm L, et al. Abnormalities of retinal metabolism in diabetes or experimental galactosaemia versus relationship between protein kinase C and ATPases. Diabetes 1998;47:464-49.
36. Jirousek MR, Gillig JR, Gonzalez CM, et al. (s)-13-[(dimthylamino)methyl] -10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H, 13H dibenzo [e,k] pyrrolo [3,4] [1,4,13] oxadiazacyclohexadecene-1,3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J Med Chem 1996;39:2664-71.
37. Ishii H, Jirousek M, Koya D, et al. Amelioration of vascular dysfunction in diabetic rats by an oral PKCβ inhibitor. Science 1996;272:728-31.
38. Bursell SE, Clermont A, Kinsley B, et al. Retinal blood flow changes in patients with IDDM-diabetes mellitus with no diabetic retinopathy: a video fluorescein angiography study. Invest Opthalmol Vis Sci 1996;37:886-97.
39. Takagi C, Bursell SE, Lin Y-W, et al. Regulation of retinal haemodynamics in diabetic rats by increased expression and action of endothelin-1. Invest Ophthalmol Vis Sci 1996;37:2504-518.
40. Chakravarthy U, Hayes R, Stitt A, et al. Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end products. Diabetes 1998;47:945-52.
41. Ronald MA, Rask-Madsen C, Yokota T, et al. Overexpression of endothelin-1 and protein kinase C-b1 isoform in vivo mimic abnormal retinal haemodynamics of diabetes. Diabetes 2003;52(Suppl 1):A20.
42. Aiello LP, Bursell SE, Devries T, et al. Protein kinase C-β-selective inhibitor LY333531 ameliorates abnormal retinal haemodynamics in patients with diabetes. Diabetes 1999;48(Suppl):A19.
43. Danis RP, Bingaman DP, Jirousek M, et al. Inhibition of intraocular neovascularization caused by retinal ischaemia in pigs by PKC-beta inhibition with LY333531 Invest Ophthalmol Vis Sci 1998;39:171-9.
44. Nonaka A, Kiryu J, Tsujikawa A, et al. PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal micracirculation of diabetic rats. Invest Ophthalmol Vis Sci 2000;41:2702-6.
45. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of DRS findings. Ophthalmology 1978;85:82-106.
46. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report No. 9. Ophthalmology 1991;98:766-85.
47. The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med 1993;329:977-86.
48. UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
49. Demolle D, de Suray JM, Onkelinx C. Pharmacokinetics and safety of multiple oral doses of LY333531, a PKC beta inhibitor, in healthy subjects. Clin Pharm Ther 1999;65:189.
50. Demolle D, de Suray JM, Vandenhende F, et al. LY333531 single escalating oral dose study in healthy volunteers. Diabetologia 1998;41(Suppl 1):A354.
51. Aiello LP, Bursell S, Devries T. Protein kinase C beta selective inhibitor LY333531 ameliorates abnormal retinal haemodynamics in patients with diabetes. Diabetes 1999;48:A19.
52. Aiello LP, Davis MD, Sheetz MJ. The PKC Inhibitor Diabetic Retinopathy Study Group. Design, baseline patient choracteristics and high prevalence of clinically significant macular edema (CSME) in patients with moderately severe to very severe nonproliferative diabetic retinopathy (NPDR) in the Protein Kinase C Diabetic Retinopathy Study (PKC-DRS). Diabetes 2002;51(Suppl 2):A209.
53. Ferris FL. How effective are treatments for diabetic retinopathy? JAMA 1993;269:1290-1.
54. Ferris FL, Davis MD, Aiello LM. Treatment of diabetic retinopathy. N Engl J Med 1999;341:667-78.
55. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation (HOPE) study investigators. N Engl J Med 2000;342:145-153.
56. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report No 12. Ophthalmology 1991;98:823-33.
57. Aldington SJ, Kohner EM, Meuer S, et al. The EURODIAB IDDM Complications Study Group. Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM Complications Study. Diabetologia 1995;38:437-44.
58. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID study group. EURODIAB Controlled Trial of Lisinopril in Insulin-dependent diabetes mellitus. Lancet 1998;35:28-31.
59. Klein R, Meuer SM, Moss SE, et al. Retinal microaneurysm counts and 10-yr progression of diabetic retinopathy. Arch Ophthalmol 1995;113:1386-91.
60. Hellstedt T, Immonen I. Disappearance and formation rates of microaneurysms in early diabetic retinopathy. Br J Ophthalmol 1996;80:135-9.
61. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular oedema. Ophthalmology 1991;98:1594-602.